Overall Survival Benefit with Tebentafusp in Metastatic Uveal MelanomaPaul Nathan, Sophie Piperno‐Neumann, Marcus O. Butler et al.|New England Journal of Medicine|2021Cited by 869
Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced MelanomaOmid Hamid, Giuseppe Gullo, Karl D. Lewis et al.|Journal of Clinical Oncology|2024Cited by 37